October 14, 2008

PanGenex (PGXC) Executives Meet With World Renowned Cardiologists at TCT Conference 2008 in Washington DC.

PanGenex Corporation (Pink Sheets: PGXC) executives including CEO and President Jeff Roman, Vice President of Product Development Jim Mosbaugh and Director and Cardiologist Ronald P. Caputo, MD, FACC, FSCAI met with leading interventional cardiologists in Washington DC over the weekend to discuss their involvement with the company as directors and to be part of the Scientific Advisory Board. Meetings were held in conjunction with the Transcatheter Cardiovascular Therapeutics (TCT) symposium. Over the past two decades, the TCT Conference has become the primary means by which state-of-the-art training and techniques are disseminated to interventionalists around the world, allowing them to bring innovative breakthroughs to their practices and dramatically improve the lives of patients with cardiovascular disease.

"I could not be more excited than to have had the humbling experience of meeting with some of the best cardiologists in the world. These professionals are on the forefront of preventive and ongoing cardiovascular care and clearly see the benefits in the PanGenex product offerings," states Jeff Roman. "Over the next two weeks we expect to add three high-profile cardiologists to our Board of Directors. These physicians not only have active cardiology practices but two of the potential directors are actively involved in business, including the management of their own venture funds."

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS: PGXC) and pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com .



This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects,""anticipates,""intends,""plans,""believes,""seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.